CLYM Stock Price | Climb Bio Inc P/E, Revenue, EPS, & Forecasts

Climb Bio Inc • CLYM

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Climb Bio Inc

Ticker

CLYM

Trading on

NASDAQ

ISIN

US28658R1068

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc

Headquarters

20 William Street, Wellesley Hills, MA, United States, 02481

Employees

Website

https://climbbio.com

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Metrics

BasicAdvanced

Market cap

$479M

P/E ratio

EPS

-$0.88

Dividend Yield

0.00%

Beta

-0.24

Forward P/E ratio

EBIDTA

$-67.8M

Ex dividend date

Price & volume

Market cap

$479M

Average daily volume

0.6M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

2.09

Earnings

EPS

-$0.88

EPS estimate (current quarter)

-$0.21

EPS estimate (next quarter)

-$0.21

EBITDA

$-67.8M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

-0.24

52-week High

$8.04

52-week Low

$1.05

50-day moving average

$5.47

200-day moving average

$2.86

Short ratio

2.82

Short %

10.78%

Management effectiveness

ROE (TTM)

-32.15%

ROA (TTM)

-22.04%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

47.8M

Float

27.9M

Insiders %

0.82%

Institutions %

76.18%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 2 analysts.

Average price target

$14.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.31

-$0.15

-106.67%

Q1 • 25Missed

-$0.13

-$0.18

27.78%

Q2 • 25Beat

-$0.19

-$0.15

-29.52%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-12.9M

-∞%

Q3 • 25

$0M

$-17.5M

-∞%

Q4 • 25

NaN%

35.91%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$182M

$5.3M

2.91%

Q3 • 25

$168M

$7.3M

4.33%

Q4 • 25

-7.99%

37.13%

49.03%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-12.1M

$15.3M

$0M

$-12.2M

Q3 • 25

$-15.6M

$25.5M

$-0M

$-15.6M

Q4 • 25

28.80%

67.35%

-∞%

27.65%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Climb Bio Inc share?

Climb Bio Inc shares are currently traded for undefined per share.

How many shares does Climb Bio Inc have?

Climb Bio Inc currently has 47.8M shares.

Does Climb Bio Inc pay dividends?

No, Climb Bio Inc doesn't pay dividends.

What is Climb Bio Inc 52 week high?

Climb Bio Inc 52 week high is $8.04.

What is Climb Bio Inc 52 week low?

Climb Bio Inc 52 week low is $1.05.

What is the 200-day moving average of Climb Bio Inc?

Climb Bio Inc 200-day moving average is $2.86.

Who is Climb Bio Inc CEO?

The CEO of Climb Bio Inc is Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc.

How many employees Climb Bio Inc has?

Climb Bio Inc has 28 employees.

What is the market cap of Climb Bio Inc?

The market cap of Climb Bio Inc is $479M.

What is the P/E of Climb Bio Inc?

The current P/E of Climb Bio Inc is null.

What is the EPS of Climb Bio Inc?

The EPS of Climb Bio Inc is -$0.88.

What is the PEG Ratio of Climb Bio Inc?

The PEG Ratio of Climb Bio Inc is null.

What do analysts say about Climb Bio Inc?

According to the analysts Climb Bio Inc is considered a buy.